Patients prescribed Prasugrel should also be taking which of the following medications?

Prasugrel is a type of antiplatelet medication that is commonly prescribed in combination with aspirin to prevent blood clots in patients, particularly those who have undergone procedures such as percutaneous coronary intervention (PCI) or who have a history of acute coronary syndrome. The dual antiplatelet therapy (DAPT) approach, which includes both prasugrel and aspirin, is effective in reducing the risk of thrombotic events after coronary stenting.

Taking aspirin alongside prasugrel enhances the overall antiplatelet effect because both medications work through different mechanisms to inhibit platelet activation and aggregation. This combination significantly improves patient outcomes by decreasing the risk of myocardial infarction (heart attack) and other cardiovascular events.

While warfarin is an anticoagulant that affects different pathways in hemostasis, clopidogrel is a similar antiplatelet agent that would not be used in combination with prasugrel due to the risk of increased bleeding without added benefit. Dipyridamole is also an antiplatelet medication but is typically not indicated for use with prasugrel in the acute coronary syndrome or PCI setting. Thus, the combination of prasugrel and aspirin is well-accepted clinical practice, making aspirin the correct choice